GSK about to sign another big bird flu deal

Europe's largest drug maker GlaxoSmithKline is said to be about to sign another deal to provide tens of millions of doses of it's experimental H5N1 vaccine for humans.

The drug giant is currently talking to the British government about the possibility of stockpiling the vaccine.

The company has already signed a contract with Switzerland to supply 8 million doses of the vaccine, enough vaccine to protect the entire population should bird flu pose a threat.

The company has also reportedly stitched up a deal with Singapore and is also thought to close to signing a deal with the French government.

The firm has also been communicating with the U.S. government with regard to the possibility of a mass vaccination programme.

Although the vaccine is yet to be granted regulatory approval by the European Medicines Agency, the company appears confident that will happen by the end of 2006.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
As California taps pandemic stockpile for bird flu, officials keep close eye on spending